As shown in Fig. 1a, we developed a biomimetic nanovaccine (biNV) via the engineering of dendritic cell (DC)-derived cytomembrane vesicles that efficiently delivered IL-15 to tumor-specific T cells for potent and safe cancer immunotherapy. This evidence concerns the gene IL15 and neoplasm.